ADC Therapeutics (ADCT) Scheduled to Post Earnings on Thursday

ADC Therapeutics (NYSE:ADCT) is scheduled to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT) last released its earnings results on Tuesday, August 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The company had revenue of $17.41 million for the quarter, compared to analysts’ expectations of $19.06 million. During the same period in the prior year, the firm earned ($0.58) EPS. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ADC Therapeutics Trading Up 1.7 %

ADC Therapeutics stock traded up $0.05 during midday trading on Tuesday, reaching $3.07. The company had a trading volume of 171,692 shares, compared to its average volume of 632,504. ADC Therapeutics has a 12-month low of $0.36 and a 12-month high of $6.04. The firm’s fifty day simple moving average is $3.01 and its 200-day simple moving average is $3.35.

Analyst Ratings Changes

ADCT has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of ADC Therapeutics in a research note on Thursday, August 8th. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price objective on shares of ADC Therapeutics in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $9.00.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.